Sandrine Aspeslagh

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease

François‐Xavier Danlos, Anne-Laure Voisin, Valérie Dyevre et al. · European Journal of Cancer · 2018 · 304 citations

Anti-programmed Death 1, Inflammatory Disease, Autoimmune Disease +13

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

Frédéric Bigot, Eduardo Castañón, Capucine Baldini et al. · European Journal of Cancer · 2017 · 215 citations

Prognostic Evaluation, Autoimmune Disease, Immunotherapy Phase +10

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma

C. Owen, Xue Bai, Serigne Lo et al. · Annals of Oncology · 2021 · 172 citations · Full text

Tumor Immunology, Melanoma, Immunology +6

Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Marie-Léa Gauci, Émilie Lanoy, Stéphane Champiat et al. · Clinical Cancer Research · 2018 · 140 citations

Pharmacological sensitivity of ATP release triggered by photoliberation of inositol‐1,4,5‐trisphosphate and zero extracellular calcium in brain endothelial cells

Katleen Braet, Sandrine Aspeslagh, Wouter Vandamme et al. · Journal of Cellular Physiology · 2003 · 116 citations